1. A method for controlling the treatment of amyloidosis, such as Alzheimer's disease, in a patient, comprising determining the degree of activation of p38 MAP kinase in the patient's glial macrophages. The method according to claim 1, in which the treatment of amyloid is carried out using antibodies against beta-amyloid. A method for testing the neuroprotective activity of an agent, comprising. incubation of glial macrophages with neurotoxic Aβ1-42 oligomers and anti-beta amyloid antibody b. measurement of absorption of beta-amyloid by glial macrophages. 4. A method of verifying agent security, including. incubation of glial macrophages with neurotoxic Aβ1-42 oligomers and anti-beta amyloid antibody b. measurement of p38 MAP kinase activation in glial macrophages. 5. The method of claim 3 or 4, wherein the agent is an anti-amyloid antibody. A method of treating amyloidosis, such as Alzheimer's disease, comprising administering to a patient in need thereof a safe and functional amount of a humanized non-IgG1 isotype anti-beta amyloid antibody, the safe and functional amount leading to activation of p38 MAP kinase in the patient’s glial macrophages at the level of which is higher than the level of p38 MAP kinase activation in the absence of a humanized, non-isotype IgG1 anti-beta amyloid antibody, but lower than the level of p38 MAP kinase activation in the presence of the concentration of antibodies against beta-amyloid isotype IgG1, that binds to beta-amyloid with the same K, which is humanized and not related to the IgG1 isotype antibody against beta-amiloida.7. The method according to claim 5, in which the activation of p38 MAP kinase in the glial macrophages of the patient is 5% -15%, 10% -20%, 15% -25%, 21. Способ контролирования курса лечения амилоидоза, такого как болезнь Альцгеймера, у пациента, включающий определение степени активации p38 MAP-киназы в глиальных макрофагах пациента.2. Способ по п.1, в котором лечение амилоида осуществляют с помощью антитела
